<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bortezomib (Velcade), thalidomide (Thalomid), and dexamethasone (VTd) induction therapy for initial treatment of patients with multiple myeloma&lt;sup&gt;[1,2]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bortezomib (Velcade), thalidomide (Thalomid), and dexamethasone (VTd) induction therapy for initial treatment of patients with multiple myeloma<sup>[1,2]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Bortezomib (Velcade), thalidomide (Thalomid), and dexamethasone (VTd) induction therapy for initial treatment of patients with multiple myeloma<sup>[1,2]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="40%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4"><strong>Cycle length:</strong> 28 days. </td> </tr> <tr class="divider_top"> <td class="subtitle1 divider_bottom">Drug</td> <td class="subtitle1 divider_bottom">Dose and route</td> <td class="subtitle1 divider_bottom">Administration</td> <td class="subtitle1 divider_bottom">Given on days</td> </tr> <tr> <td>Bortezomib*</td> <td>1.3 mg/m<sup>2</sup> SC</td> <td>Given as a single SC injection.</td> <td>Days 1, 8, 15, and 22<sup>[1,2]</sup></td> </tr> <tr> <td>Thalidomide<sup>¶</sup></td> <td>100 mg for first 14 days then 200 mg per day thereafter by mouth</td> <td>Take with water on an empty stomach at least one hour after the evening meal.</td> <td>Daily, days 1 through 21</td> </tr> <tr class="divider_bottom"> <td>Dexamethasone<sup>Δ</sup> ("low dose")</td> <td>40 mg by mouth</td> <td>Take with food (after meals or with food or milk) in the morning.</td> <td>Days 1, 8, 15, and 22<sup>[1,2]</sup></td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Pretreatment considerations:</td> </tr> <tr> <td class="indent1"><strong>Emesis risk</strong></td> <td colspan="3"> <ul> <li>MINIMAL TO LOW. </li> <li>Refer to UpToDate topics on prevention of chemotherapy-induced nausea and vomiting in adults. </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan="3"> <ul> <li>Routine premedication is not indicated. If a hypersensitivity reaction (not including local reactions) occurs with bortezomib or thalidomide, then neither drug should be readministered. </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Antithrombotic prophylaxis</strong></td> <td colspan="3"> <ul> <li>Routine antithrombotic prophylaxis is warranted. Thromboembolism (grade 3 and 4) was reported in 3% of patients in a clinical trial receiving VTd despite antithrombotic prophylaxis.<sup>[2]</sup> In addition, reported risk of thromboembolism (grade 3 and 4) was 5% in the Td arm of this study.<sup>[2]</sup> </li> <li>Refer to UpToDate topics on multiple myeloma, prevention of venous thromboembolism in patients receiving immunomodulatory drugs (thalidomide, lenalidomide, and pomalidomide). </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Infection prophylaxis</strong></td> <td colspan="3"> <ul> <li>Bortezomib therapy may be associated with an increased risk of herpes zoster and infections not related to neutropenia. Antiviral prophylaxis (eg, acyclovir 400 mg orally twice a day) should be administered to all patients receiving VTd. Some clinicians also administer trimethoprim-sulfamethoxazole double strength once daily on Mondays, Wednesdays, and Fridays during treatment.<sup>[1,2]</sup> Primary prophylaxis with G-CSF is not indicated. </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Vesicant/irritant properties</strong></td> <td colspan="3"> <ul> <li>Bortezomib is an irritant. </li> <li>Refer to UpToDate topics on extravasation injury from chemotherapy and other non-antineoplastic vesicants. </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan="3"> <ul> <li><strong>Bortezomib:</strong> No dosage adjustment for bortezomib secondary to renal insufficiency is necessary. For patients undergoing hemodialysis, bortezomib should be administered after dialysis. Patients with moderate or severe hepatic impairment (serum bilirubin level &gt;1.5 times the upper limit of normal) should be started on bortezomib at a reduced dose of 0.7 mg/m<sup>2</sup> per injection during the first cycle, with further dose modifications based upon patient tolerance.<sup>[3]</sup></li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents and chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents.</li> <li><strong>Thalidomide:</strong> Dosage adjustment of thalidomide is not required for either preexisting renal or hepatic dysfunction.<sup>[4]</sup> </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Pregnancy warning</strong></td> <td colspan="3"> <ul> <li>Thalidomide can result in severe, life-threatening human birth defects. Pregnancy testing is required within 24 hours prior to initiation of thalidomide therapy.<sup>[4]</sup> </li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Monitoring parameters:</td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Assess CBC with differential, electrolytes, renal function, liver function, and M protein prior to starting each cycle. A CBC should also be performed prior to the dose of bortezomib on days 1, 8, 15, and 22. </li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for signs of neuropathy. Many clinicians provide a prophylactic bowel regimen for patients taking thalidomide. </li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for hypotension during therapy; adjustment of antihypertensives and/or administration of IV hydration may be needed. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for signs of rash, infection, or thrombotic event periodically. </li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class="indent1"><strong>Neuropathy</strong></td> <td colspan="3"> <ul> <li>Dose adjustment guidelines for bortezomib in patients who develop peripheral neuropathy or neuropathic pain are available.<sup>[3]</sup> </li> <li>Refer to UpToDate topics on overview of neurologic complications of conventional non-platinum cancer chemotherapy. </li> <li>Thalidomide should be discontinued or dose reduced if a patient develops paresthesias accompanied by pain, motor deficit, or interference with activities of daily living. </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Rash</strong></td> <td colspan="3"> <ul> <li>Thalidomide has been associated with rashes including SJS and TEN. If a rash develops, thalidomide should be discontinued and the rash further evaluated. Thalidomide should not be administered again if the rash is exfoliative, purpuric, or bullous, or if SJS or TEN is suspected.<sup>[4]</sup> </li> <li>Refer to UpToDate topics on cutaneous side effects of conventional chemotherapy agents. </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Thrombotic microangiopathy</strong></td> <td colspan="3"> <ul> <li>Rarely, bortezomib has been associated with TMA, which can present with Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings.<sup>[3]</sup> If TMA is suspected, stop bortezomib and evaluate. </li> <li>Refer to UpToDate topics on drug-induced thrombotic microangiopathy.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Other nonhematologic toxicity</strong></td> <td colspan="3"> <ul> <li>For grade 3 or 4 nonhematologic toxicity other than neuropathy, bortezomib should be held. Once symptoms have resolved to grade 1 or baseline, bortezomib may be reinitiated with one dose level reduction (from 1.3 mg/m<sup>2</sup> to 1 mg/m<sup>2</sup>, or from 1 mg/m<sup>2</sup> to 0.7 mg/m<sup>2</sup>).<sup>[2,3]</sup> </li> </ul> </td> </tr> <tr class="divider_top"> <td class="highlight_gray_text" colspan="4" style="font-size: 1.2em;"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class="graphic_footnotes">SC: subcutaneous; G-CSF: granulocyte-colony stimulating factor; CBC: complete blood count; IV: intravenous; SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis; TMA: thrombotic microangiopathy.<br/>* SC administration is preferred due to a lower risk of neuropathy. If there are problems with SC administration such as anasarca or allergy, then bortezomib can be given intravenously as a rapid bolus over 3 to 5 seconds.<br/>¶ In the United States, the use of thalidomide is subject to the THALOMID REMS program (formerly called the S.T.E.P.S. Program, <a href="http://www.THALOMIDREMS.com" target="_blank">www.THALOMIDREMS.com</a>) developed in an attempt to minimize the potential for pregnancy among patients taking this medication and associated birth defects.<br/>Δ These are the most commonly used doses/schedule of bortezomib, thalidomide, and dexamethasone in the VTd regimen. They are different than those described in the original report<sup>[1]</sup> due to subsequent data that show lower toxicity with similar efficacy.<sup>[2]</sup></div><div class="graphic_reference">References:

<ol>
<li>Rajkumar S. Am J Hematol 2014; 89:999.</li>
<li>Cavo M, et al. Lancet 2010; 376:2075.</li>
<li>Bortezomib injection. United States prescribing information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on March 4, 2020).</li>
<li>Thalidomide. United States prescribing information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on January 26, 2015).</li>
</ol></div><div id="graphicVersion">Graphic 101205 Version 8.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
